These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 22509073)
61. Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells. Trabulo S; Aires A; Aicher A; Heeschen C; Cortajarena AL Biochim Biophys Acta Gen Subj; 2017 Jun; 1861(6):1597-1605. PubMed ID: 28161480 [TBL] [Abstract][Full Text] [Related]
62. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Binenbaum Y; Na'ara S; Gil Z Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340 [TBL] [Abstract][Full Text] [Related]
63. Establishment of pancreatic cancer stem cells by flow cytometry and their biological characteristics. Li D; Su D; Xue L; Liu Y; Pang W Int J Clin Exp Pathol; 2015; 8(9):11218-23. PubMed ID: 26617845 [TBL] [Abstract][Full Text] [Related]
64. Nimbolide-encapsulated PLGA nanoparticles induces Mesenchymal-to-Epithelial Transition by dual inhibition of AKT and mTOR in pancreatic cancer stem cells. Singh D; Mohapatra P; Kumar S; Behera S; Dixit A; Sahoo SK Toxicol In Vitro; 2022 Mar; 79():105293. PubMed ID: 34883246 [TBL] [Abstract][Full Text] [Related]
65. Biomarkers for early diagnosis of pancreatic cancer. Jenkinson C; Earl J; Ghaneh P; Halloran C; Carrato A; Greenhalf W; Neoptolemos J; Costello E Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):305-15. PubMed ID: 25373768 [TBL] [Abstract][Full Text] [Related]
66. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Du Z; Qin R; Wei C; Wang M; Shi C; Tian R; Peng C Dig Dis Sci; 2011 Mar; 56(3):741-50. PubMed ID: 20683663 [TBL] [Abstract][Full Text] [Related]
67. Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters. Dauer P; Nomura A; Saluja A; Banerjee S Pancreatology; 2017; 17(1):7-12. PubMed ID: 28034553 [TBL] [Abstract][Full Text] [Related]
68. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. Delitto D; Vertes-George E; Hughes SJ; Behrns KE; Trevino JG World J Gastroenterol; 2014 Jul; 20(26):8458-70. PubMed ID: 25024602 [TBL] [Abstract][Full Text] [Related]
69. Novel strategies for managing pancreatic cancer. Loc WS; Smith JP; Matters G; Kester M; Adair JH World J Gastroenterol; 2014 Oct; 20(40):14717-25. PubMed ID: 25356034 [TBL] [Abstract][Full Text] [Related]
70. Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells. Barman S; Fatima I; Singh AB; Dhawan P Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946266 [TBL] [Abstract][Full Text] [Related]
71. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Shapira A; Livney YD; Broxterman HJ; Assaraf YG Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184 [TBL] [Abstract][Full Text] [Related]
72. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. Tomihara H; Carbone F; Perelli L; Huang JK; Soeung M; Rose JL; Robinson FS; Lissanu Deribe Y; Feng N; Takeda M; Inoue A; Poggetto ED; Deem AK; Maitra A; Msaouel P; Tannir NM; Draetta GF; Viale A; Heffernan TP; Bristow CA; Carugo A; Genovese G Cancer Res; 2021 Jan; 81(2):332-343. PubMed ID: 33158812 [TBL] [Abstract][Full Text] [Related]
73. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX. Palagani V; El Khatib M; Kossatz U; Bozko P; Müller MR; Manns MP; Krech T; Malek NP; Plentz RR PLoS One; 2012; 7(10):e46514. PubMed ID: 23094026 [TBL] [Abstract][Full Text] [Related]
74. Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis. Haque I; Mehta S; Majumder M; Dhar K; De A; McGregor D; Van Veldhuizen PJ; Banerjee SK; Banerjee S Mol Cancer; 2011 Jan; 10():8. PubMed ID: 21232118 [TBL] [Abstract][Full Text] [Related]
75. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008 [TBL] [Abstract][Full Text] [Related]
76. Cancer Stem Cell Marker CD44 Plays Multiple Key Roles in Human Cancers: Immune Suppression/Evasion, Drug Resistance, Epithelial-Mesenchymal Transition, and Metastasis. Dzobo K; Sinkala M OMICS; 2021 May; 25(5):313-332. PubMed ID: 33961518 [TBL] [Abstract][Full Text] [Related]
77. Noncoding RNAs in drug-resistant pancreatic cancer: A review. Lin Z; Lu S; Xie X; Yi X; Huang H Biomed Pharmacother; 2020 Nov; 131():110768. PubMed ID: 33152930 [TBL] [Abstract][Full Text] [Related]
78. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763 [TBL] [Abstract][Full Text] [Related]
79. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis. Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677 [TBL] [Abstract][Full Text] [Related]
80. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Noma B; Sasaki T; Fujimoto Y; Serikawa M; Kobayashi K; Inoue M; Itsuki H; Kamigaki M; Minami T; Chayama K Int J Oncol; 2008 Dec; 33(6):1187-94. PubMed ID: 19020751 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]